The recent World Health Organization (WHO) classification clearly defined a new entity, named 'myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB and FGFR1', as a category of three rare specific but related disease groups. 1 They are characterized by the formation of a fusion gene encoding an aberrant tyrosine kinase and almost always associated with peripheral blood eosinophilia. 1 Myeloid and lymphoid neoplasms with PDGFRA rearrangement are unique disease entities mostly characterized by the formation of a fusion gene FIP1L1-PDGFRA, as a result of a cryptic deletion at chromosome 4q12. 1, 2 The disease presents generally as chronic eosinophilic leukemia but can also present as acute myeloid leukemia, T-lymphoblastic lymphoma or both simultaneously. Although the hematopoietic stem cell has been postulated as a possible cellular origin of the disease, clinical manifestations are apparently limited only to the myeloid and T-cell lineages both in chronic phase and in acute leukemic transformation. 1, 2 In this study we present an extremely rare case, in which a single genetic abnormality (PDGFRA rearrangement) led to multiple morphologically and immunophenotypically distinct diseases, including T-lymphoblastic lymphoma, a myeloproliferative neoplasm with eosinophilia and abnormal mastocytosis, and a precursor B-cell acute lymphoblastic leukemia, thus involving all three major hematopoietic lineages, that is, myeloid, T-cell and B-cell in the same patient, truly representing a 'pluripotent hematopoietic stem cell disorder. ' The patient was a 42-year-old Filipino male who had a reported long history of persistent eosinophilia and was evaluated and followed at an outside hospital, but no treatment was given. In October 2008, the patient was found to have a right axillary mass/enlarged lymph node and was subsequently biopsied at that hospital, which revealed a 'T/NK cell lymphoma'. The patient received four cycles of CHOP-based chemotherapy after the initial diagnosis. In November 2008, the patient was transferred to the City of Hope National Medical Center (COHNMC) for further management. The outside axillary mass biopsy was reviewed at COHNMC and additional immunohistochemical studies were performed. The biopsy demonstrated involvement of the T-cell lymphoblastic lymphoma in the axillary lymph node. The diagnosis was confirmed by immunohistochemical studies showing that the tumor cells were positive for CD3 and TdT, and aberrant double positive for CD4 and CD8 but completely negative for B-cell or myeloid cell antigens (Figures 1a-c) . At the time of admission to COHNMC, the patient had marked leukocytosis, eosinophilia and anemia with a white blood cell count of 24.6 K/ml, with 65% circulating eosinophils, a hemoglobin of 10.6 g per 100 ml, and platelets of 199 K/ml. A bone marrow biopsy was performed and revealed a hypercellular marrow with features consistent with myeloproliferative neoplasm with marked eosinophilia and abnormal accumulation of marrow neoplastic mast cells (Figures 1c,d,f) . Conventional cytogenetic analysis demonstrated a normal male chromosomal karyotype 46 X;Y and further molecular analysis yielded no evidence of BCR/ABL transcripts or JAK-2 V617F mutation. On the basis of the clinical manifestation of combined peripheral blood eosinophilia, bone marrow myeloproliferative disorder and T-cell lymphoblastic lymphoma in the axillary mass of the patient, we entertained the possibility of a newly recognized entity in the 2008 WHO classification as 'myeloid and lymphoid neoplasms with PDGFRA rearrangement'. Therefore, we performed cytogenetic and molecular studies and found that CHIC2 gene deletion (a marker of indicating FIP1LI-PDGFRA translocation) was clearly identified by florescence in situ hybridization in both the bone marrow biopsy (47%) and axillary mass biopsy (81%) specimens, respectively, indicating the presence of FIP1L1-PDGFRA translocation in neoplastic myeloid and T-lymphoid cells of both lesions, providing strong evidence to support the diagnosis. The patient was subsequently treated with Dasatinib at the dose of 100 mg daily and followed by 70 mg twice a day, and showed a good response with evidence of continued decrease in total white blood cell counts and peripheral blood eosinophilia.
In December 2009, the patient suddenly developed marked leukocytosis with numerous circulating blasts (Figure 2a) . The peripheral blood evaluation and subsequent bone marrow biopsy were immediately performed and demonstrated that the bone marrow and peripheral blood were markedly involved by a typical acute lymphoblastic leukemia. The neoplasm showed the characteristic immunophenotypic features of a precursor B-cell, with the leukemic blasts positive for CD19, CD10, TdT, cytoplasmic CD22 and PAX-5, but completely negative for myeloid or T-cell antigen expression by flow cytometry and immunohistochemistry analysis, respectively (Figures 2b-d ). Molecular studies demonstrated the presence of clonal immunoglobulin heavy and kappa light chain gene rearrangements as well as T-cell receptor gamma gene rearrangements in the same population, suggesting a lineage infidelity of the neoplasm. Florescence in situ hybridization study clearly demonstrated CHIC2 gene deletion in 87% of neoplastic lymphoblasts, indicating that they carried the same genetic abnormality (Figure 2e ). Again, no evidence of BCR/ABL transcripts or JAK-2 V617F mutation was identified by molecular analysis. Further conventional cytogenetic analysis of the bone marrow biopsy revealed the presence of monosomy 7 and t(8;13) (q24.3;q14) translocation in 20/20 cells of the lymphoblastic population, indicating the same disease with clonal evolution (Figure 2f ). The patient was treated immediately with two courses of hyper-CVAD chemotherapy and went into remission quickly. He then underwent allogeneic stem cell transplantation in January 2010 and to date remains in clinical and cytogenetic remission. This is a very unique and extremely interesting case. The patient initially had typical presentations with both bone marrow chronic myeloproliferative disorders with eosinophilia and atypical accumulation of neoplastic mast cells and T-lymphoblastic lymphoma in the lymph node simultaneously. Florescence in situ hybridization analysis clearly demonstrated that both myeloid and T-lymphoid lesions shared the same chromosomal abnormality with FIP1L1-PDGFRA translocation, which has well been recognized by the recent WHO classification as a new disease entity and has been reported in the literature.
1,2 Acute phase of the disease may occur, usually myeloid or T-lymphoblastic, according to the WHO classification.
1,2 However, the current patient developed a rather characteristic precursor B-cell acute lymphoblastic leukemia during the course of treatment, a little more than 1 year after his initial diagnosis. Cytogenetic and molecular analysis unequivocally demonstrated the presence of FIP1L1-PDGFRA translocation in the T-lymphoblastic lymphoma and chronic myeloproliferative neoplasm, presumably including eosinophils and mast cells and the later precursor B-cell acute lymphoblastic leukemia. The results clearly show that the three distinctive disorders shared a common fundamental molecular genetic abnormality and indicate that they may undergo a common process in pathogenesis. Additional chromosomal abnormalities identified in precursor B-cell acute lymphoblastic leukemia indicated clonal evolution of the disease, whereas the exact pathogenesis and mechanism of multilineage involvement and manifestation of the disease bearing a single known molecular genetic abnormality in FLP1L1-PDGFRA translocation, however, remains to be elucidated. To the best of our knowledge, PDGFRA rearrangement cases with evolution to precursor B-cell acute lymphoblastic leukemia have not been recognized by the new 2008 WHO Classification and have not been described in the literature. 1, 2 A clonal relationship between phenotypically different neoplasms is always questioned when they occur in the same patient in either a synchronous or a sequential manner. Although the concepts of 'de-differentiation' or 'trans-differentiation' of those morphological and immunophenotypic distinctive neoplasms have been proposed, a more plausible mechanism for Letters to the Editor the multilineage or cross-lineage transformation from, for example in the current case, differentiated and mature myeloid malignancies to a phenotypically distinctive immature lymphoid neoplasm would be the presence of a common progenitor shared by two or more lesions in the same patients. [3] [4] [5] [6] Human chronic myelogenous leukemia may serve as a good example of this model, in which a genetic alteration and neoplastic transformation occurs at the hematopoietic stem cell level, and subsequently this mature myeloid neoplasm frequently converts to lymphoid lineage in blast phase. 7 Hou et al. 8 reported that a small fraction of B-cell progenitors have the potential to undergo myeloid differentiation under myeloid culture conditions, thus proposing the presence of B-cell/myeloid common progenitors in human bone marrow. This concept of B-cell/myeloid common progenitor is in agreement with recent findings of high frequencies of clonal immunoglobulin heavy or kappa light chain gene rearrangement in sporadic histiocytic sarcomas 9 and immunoglobulin heavy chain as well as T-cell receptor gene rearrangements in a fraction of acute myeloid leukemia. 10 In theory, an initial genetic mutation occurring at an uncommitted progenitor cell level either immortalizes the clone or causes a genomic instability in the clone, and then a 'second hit' of either genetic or epigenetic changes seals the fate of neoplastic differentiation. Even in the case of chronic myeloid leukemia, the pathogenesis of which is well known, multilineage involvement with clinical manifestations of distinctive disease is usually limited to either myeloid/B-cell or myeloid/ T-cell lineage involvement but not both. The multilineage involvement in myeloid, T-cell and B-cell disorders in the same chronic myeloid leukemia patient has not been reported. Furthermore, clonal evolution is usually a natural course of neoplastic process, largely as a result of neoplastic cell genomic instability. Whether or not medical intervention has a role in the transformation or clonal evolution process during the disease course is still an issue of debate. To further characterize this disorder, we performed comparative genomic hybridization (CGH)-based Affymetrix array analysis by using genomic DNA isolated from specimens of the three distinctive lesions, namely the axillary lymph node with T-lymphoblastic lymphoma, the bone marrow with chronic myeloproliferative disorder with eosinophilia and atypical mastocytosis and the bone marrow with precursor B-cell acute lymphoblastic leukemia, respectively, to look for chromosome copy number changes in the whole genome. As expected, in addition to common FIP1L1-PDGFRA translocation demonstrated by florescence in situ hybridization analysis in those lesions, the three distinctive disorders had also shared many additional common chromosomal abnormalities, predominantly with chromosome copy number loss (Table 1) , further indicating a common pathogenesis of the disease processes. Some chromosomal abnormalities seemed to be limited to myeloid/B-lymphoid, myeloid/T-lymphoid or B/Tlymphoid lesions, respectively, strongly suggesting the presence of common myeloid/B-cell, myeloid/T-cell or T/B-cell progenitors. Interestingly, a few unique chromosomal abnormalities seemed only limited to a single lineage, but were not identified in others, indicating lineage differentiation or unique pathogenesis toward that particular lesion. As an example, unique chromosomal loss in 5q13.1;5q35.2;13q21.1 in T-lymphoblastic lymphoma, 12q12 loss in myeloproliferative neoplasm with eosinophilia and abnormal mastocytosis and 7q35 loss in precursor B-acute lymphoblastic leukemia were identified (Table 1 ). These results suggest that the genetic heterogeneity in cancer-initiating cells (clones) may be indeed present even within the 'hematopoietic stem cell compartment' and provide further evidence for the concept of hematopoietic stem cell plasticity and lineage infidelity of the neoplasm. Table 1 Chromosomal copy number changes in T-lymphoblastic lymphoma, chronic myeloproliferative neoplasm and precursor B-cell acute lymphoblastic leukemia determined by CGH Affymetrix array analysis Common chromosomal loss presents in all three lesions: 1p36.33; 2p11;2q13;7p11;9p11;9p12;9q12;11p11;14q11;21p11;22q11 Common chromosomal loss presents in B-and T-cell lesions: 1p12;1p36.21;1q21;7p22;7q36 Common chromosomal loss presents in B and myeloid lesions: 8p11;19p12 Common chromosomal loss presents in T and myeloid lesions: 10p11;16p11 Unique chromosomal loss in: T-cell lesion: 5q13.1;5q35.2;13q21.1 Myeloid lesion: 12q12 B-cell lesion: 7q35 Note: CGH-based array was performed based on Cytogenetics Whole-Genome 2.7 M array (Affymetrix) and was analyzed by using Affymetrix Chromosome Analysis Suite (ChAS) software according to the manufacturer's instruction (Santa Clara, CA, USA). The transforming growth factor (TGF)-b superfamily has been implicated into different physiological and pathological processes in a broad range of cell systems, including fibroblasts, immune, stem, endothelial, mural and tumor cells. With three TGF-b isoforms, three activin isoforms and over 20 bone morphogenic proteins (BMPs), the TGF-b superfamily represents a complex signaling pathway. The TGF-b receptor complex is composed of type I, type II and accessory receptors. There are seven isoforms of type I receptors termed activin receptor-like kinases (ALKs) 1-7. Targeted inactivation of TGF-b signaling components in mice revealed the pathway's crucial role in vascular morphogenesis as animals lacking various TGF-b superfamily members die at mid-gestation during embryogenesis because of defects in vascular development. In humans, dysregulation of the pathway is responsible for a broad range of diseases, including vascular diseases, hereditary cancer syndromes and the autosomal-dominant disorder Hereditary Hemorrhagic Teleangiectasia (also named Rendu-Osler-Weber syndrome). In leukemia, the role of TGF-b has been infrequently studied. It has been reported to either stimulate the growth of leukemic blasts in vitro or to reduce blast cell proliferation, thereby rendering them insensitive to chemotherapy (reviewed in Otten et al. 1 ). In acute myeloid leukemia, bone marrow neoangiogenesis has an important pathogenetic role. Increased microvessel density in bone marrow sections from acute myeloid leukemia (AML) patients compared with those patients with reactive disorders has been found. This increase of endothelial cells is accomplished by enhanced production of angiogenic growth factors. Secondly, hematopoietic and endothelial cells are derived from a common precursor, the hemangioblast. Therefore, many surface antigens are shared between both cell types such as CD34 or receptors for vascular endothelial growth factor (VEGF) (reviewed in Ayala et al.
2 ). Hence, we reasoned that the TGF-b superfamily receptors ALK-1 and ALK-5, which have an important role in endothelial cells (EC) behavior, might be involved in the pathogenesis of AML.
In this study, we therefore analyzed expression and prognostic relevance of endothelium-specific ALK-1, ubiquitously expressed ALK-5 and their ligands TGF-b1, BMP-9 and BMP-10 by quantitative PCR (Light Cycler (Roche, Basel, Switzerland) using the FAST Start DNAMaster Sybr Green Kit (Roche)) in pretherapeutic bone marrow or peripheral blood samples from 93 patients with newly diagnosed AML enrolled into the AustrioGerman AMLSG study group (AMLSG 07-04 study). All patients were treated according to a uniform chemotherapy protocol (for details see http://clinicaltrials.gov/ Identifier: NCT00151242). Comprehensive patient's characteristics are listed in Table 1 .
Expression levels of all analyzed genes were quantified as a ratio to the housekeeping gene GAPDH. With 82% and 88% respectively, expression of ALK-1 and ALK-5 m-RNA was detected in the majority of AML patients. Only 8 and 13% of AML patients expressed the ALK-1-specific ligands BMP-9 and 
